- Poster presentation
- Open Access
P009: Epidemiology, microbiology and outcome of community-οnset gram-negative bacteremias in a Greek University Hospital
https://doi.org/10.1186/2047-2994-2-S1-P9
© Gikas et al; licensee BioMed Central Ltd. 2013
Published: 20 June 2013
Keywords
- Dementia
- Cephalosporin
- Aminoglycosides
- Quinolones
- Antimicrobial Resistance
Introduction
According to the new classification community-onset bacteremias (COB) are divided in healthcare-associated (HCAB) and community-acquired (CAB). The objective of this study was to apply this classification to a cross-sectional study of patients with COB and to determine differences between the two groups in terms of epidemiology, treatment and outcome.
Methods
The study was conducted at the University Hospital of Heraklion, Greece, from March 2010 to November 2011. Patients were classified as HCAB or CABusing pre-defined selection criteria. Epidemiological, clinical and therapeutic characteristics, antimicrobial resistance and outcome were compared in both groups. The statistical analysis was performed using SPSS 19.0.
Results
Αmong 145 patients with gram-negative COB, 83 (57.2%) had HCAB and 62 (42.8%) had CAB. The frequency of malignant tumors, renal insufficiency and dementia was higher in patients with HCAB than with CAB. In both groups Escherichia coli was the mostcommon causative agent but the prevalence of Klebsiella pneumoniae in HCAB was significantly higher than CAB (19.3% vs. 4.8%). Patients with HCAB had higher Charlson score and higher Pitt bacteremia score, less frequent administration of appropriate empirical antibiotic treatment and higher probability of death than patients with CAB.
The antimicrobial resistance in HCAB και CAB patients respectively, was found 27/83 (32.5%) vs. 4/62 (6.5%) (P<.001) to third-generation cephalosporins (3GC), 22/83 (26.5%) vs. 7/62 (11.3%) (P=.021) to aminoglycosides, 29/83 (34.9%) vs. 9/62 (14.5%) (P=.005) to quinolones. Bacteria that produced ESBL were 16/76 (21.1%) vs. 2/59 (3.4%) (P=.003), and carbapenem-resistant were 10/83 (12.0%) vs. 2/62 (3.2%) (P=.056) in HCAB και CAB patients respectively
Conclusion
There are significant differences in the severity of underlying diseases, causative pathogens, antibiotic resistance, outcome and treatment between the two groups. In our region 3GC, aminoglycosides or fluoroquinolones are proposed as appropriate empirical treatment for patients with CAB, whereas in patients with HCAB carbapenems should be the initial therapy
Disclosure of interest
None declared
Authors’ Affiliations
Copyright
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
